This “Collagen inhibitors - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Collagen inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Collagen is an essential part of the framework of the design of our various body tissues. It is the major insoluble fibrous protein in the extracellular matrix and in connective tissue.
Function -Collagen is a member of a family of naturally occurring proteins. It is one of the most plentiful proteins present in mammals and it is responsible for performing a variety of important biological functions. It is most well-known for the structural role it plays in the body. It is present in large quantities in connective tissue and provides tendons and ligaments with tensile strength and skin with elasticity. It often works in conjuction with other important proteins such as keratin and elastin.
Collagen inhibitors- Inhibition of collagen formation is an attractive target to reduce excessive formation of fibrotic tissue. Unlike canonical inhibitors of excessive accumulation of collagen-rich deposits, inhibition of collagen fibril formation targets a specific, extracellular event. Blocking collagen fibril formation may serve as an independent or supporting method to reduce excessive, localized accumulation of collagen-rich deposits.Antibody-based inhibitors of collagen fibril formation are promising therapeutic agents with a potential to limit localized fibrosis in a number of tissues.
This segment of the Collagen inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Remlarsen: miRagen Therapeutics
Remlarsen is a microRNA-29 replacement therapy, being developed by miRagen Therapeutics for the treatment of eye disorders. The drug is currently in preclinical stage for the treatment of eye disorders. In preclinical studies Remlarsen treatment appeared to reduce corneal hazing and scarring beginning at 10 days post-burn. Dose and treatment schedule were optimized in preparation for enabling toxicology studies to support human clinical trials.
Hydronidone: Shanghai Genomics
Hydronidone is a Collagen inhibitor being developed by Shanghai Genomics for several indications. The drug is in phase 2 of clinical trial for the treatment of Hepatic fibrosis.
There are approx. 10+ key companies which are developing the Collagen inhibitors. The companies which have their Collagen inhibitors drug candidates in the most advanced stage, i.e. phase 2 include, miRagen Therapeutics.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Collagen inhibitors therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Collagen inhibitors drugs.
The companies and academics are working to assess challenges and seek opportunities that could influence Collagen inhibitors R&D. The therapies under development are focused on novel approaches for Collagen inhibitors.
Geography Covered
- Global coverage
Collagen inhibitors Understanding
Collagen inhibitors: Overview
Collagen is an essential part of the framework of the design of our various body tissues. It is the major insoluble fibrous protein in the extracellular matrix and in connective tissue.
Function -Collagen is a member of a family of naturally occurring proteins. It is one of the most plentiful proteins present in mammals and it is responsible for performing a variety of important biological functions. It is most well-known for the structural role it plays in the body. It is present in large quantities in connective tissue and provides tendons and ligaments with tensile strength and skin with elasticity. It often works in conjuction with other important proteins such as keratin and elastin.
Collagen inhibitors- Inhibition of collagen formation is an attractive target to reduce excessive formation of fibrotic tissue. Unlike canonical inhibitors of excessive accumulation of collagen-rich deposits, inhibition of collagen fibril formation targets a specific, extracellular event. Blocking collagen fibril formation may serve as an independent or supporting method to reduce excessive, localized accumulation of collagen-rich deposits.Antibody-based inhibitors of collagen fibril formation are promising therapeutic agents with a potential to limit localized fibrosis in a number of tissues.
Collagen inhibitors Emerging Drugs Chapters
This segment of the Collagen inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Collagen inhibitors Emerging Drugs
Remlarsen: miRagen Therapeutics
Remlarsen is a microRNA-29 replacement therapy, being developed by miRagen Therapeutics for the treatment of eye disorders. The drug is currently in preclinical stage for the treatment of eye disorders. In preclinical studies Remlarsen treatment appeared to reduce corneal hazing and scarring beginning at 10 days post-burn. Dose and treatment schedule were optimized in preparation for enabling toxicology studies to support human clinical trials.
Hydronidone: Shanghai Genomics
Hydronidone is a Collagen inhibitor being developed by Shanghai Genomics for several indications. The drug is in phase 2 of clinical trial for the treatment of Hepatic fibrosis.
Collagen inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Collagen inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on Collagen inhibitors
There are approx. 10+ key companies which are developing the Collagen inhibitors. The companies which have their Collagen inhibitors drug candidates in the most advanced stage, i.e. phase 2 include, miRagen Therapeutics.
Phases
This report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Collagen inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Collagen inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Collagen inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Collagen inhibitors drugs.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Collagen inhibitors R&D. The therapies under development are focused on novel approaches for Collagen inhibitors.
Collagen inhibitors Report Insights
- Collagen inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Collagen inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Scenario and Emerging Therapies:
- How many companies are developing Collagen inhibitors drugs?
- How many Collagen inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Collagen inhibitors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Collagen inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Collagen inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- miRagen Therapeutics
- Shanghai Genomics
- Matrizyme
- Roche
- NeuMedics
- Processa Pharmaceuticals
Key Products
- Remlarsen
- Hydronidone
- MZ-004
- Pirfenidone
- NM 108
- Halofuginone
Table of Contents
IntroductionExecutive Summary
Collagen inhibitors: Overview
- Structure
- Mechanism of Action
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Collagen inhibitors - Analytical Perspective
In-depth Commercial Assessment
- Collagen inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Collagen inhibitors Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Pre-registration)
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Remlarsen : miRagen Therapeutics
- Product Description
- Research and Development
Comparative Analysis
Hydronidone : Shanghai Genomics
- Product Description
Research and Development
- Product Development Activities
- Research and Development
- Product Development Activities
Pre-clinical and Discovery Stage Products
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Collagen inhibitors Key Companies
Collagen inhibitors Key Products
Collagen inhibitors- Unmet Needs
Collagen inhibitors- Market Drivers and Barriers
Collagen inhibitors- Future Perspectives and Conclusion
Collagen inhibitors Analyst Views
Collagen inhibitors Key Companies
AppendixList of Tables
Table 1 Total Products for Collagen inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Collagen inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- miRagen Therapeutics
- Shanghai Genomics
- Matrizyme
- Roche
- NeuMedics
- Processa Pharmaceuticals
